Recommendation of the President – Talvey (talquetamab)
On 3 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 134/2024 on the appraisal Talvey (talquetamab) under the drug program “Treatment of patients with plasmocytic myeloma (ICD 10: C90.0)”